PMID- 32194225
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1873-7544 (Electronic)
IS  - 0306-4522 (Linking)
VI  - 439
DP  - 2020 Jul 15
TI  - ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System.
PG  - 48-61
LID - S0306-4522(20)30152-4 [pii]
LID - 10.1016/j.neuroscience.2020.03.009 [doi]
AB  - Myasthenia gravis (MG) is a relatively rare neurological disease that is usually 
      associated with antibodies to the acetylcholine receptor (AChR). These antibodies 
      (Abs) cause loss of the AChRs from the neuromuscular junction (NMJ), resulting in 
      muscle weakness that can be life-threatening. Another form of the disease is 
      caused by antibodies to muscle specific kinase (MuSK) that result in impaired 
      AChR clustering and numbers at the NMJ, and may also interfere with presynaptic 
      adaptive mechanisms. Other autoimmune disorders, Lambert Eaton myasthenic 
      syndrome and acquired neuromyotonia, are associated with antibodies to 
      presynaptic voltage-gated calcium and potassium channels respectively. All four 
      conditions can be diagnosed by specific clinical features, electromyography and 
      serum antibody tests, and can be treated effectively by a combination of 
      pharmacological approaches and procedures that reduce the levels of the IgG 
      antibodies. They form the first of a spectrum of diseases in which serum 
      autoantibodies bind to extracellular domains of neuronal proteins throughout the 
      nervous system and lead to constellations of clinical features including 
      paralysis, sensory disturbance and pain, memory loss, seizures, psychiatric 
      disturbance and movement disorders. This review will briefly summarize the ways 
      in which this field has developed, since the 1970s when considerable 
      contributions were made in Ricardo Miledi's laboratory at UCL.
CI  - Copyright (c) 2020 IBRO. Published by Elsevier Ltd. All rights reserved.
FAU - Vincent, Angela
AU  - Vincent A
AD  - Nuffield Department of Clinical Neurosciences, University of Oxford, John 
      Radcliffe Hospital, OX3 9DU, UK. Electronic address: 
      Angela.vincent@ndcn.ox.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200317
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
SB  - IM
MH  - Central Nervous System
MH  - Humans
MH  - *Isaacs Syndrome
MH  - *Lambert-Eaton Myasthenic Syndrome
MH  - *Myasthenia Gravis
MH  - Neuromuscular Junction
OTO - NOTNLM
OT  - acetylcholine receptor
OT  - antibody
OT  - muscle specific kinase
OT  - neurological disease
OT  - neuromuscular junction
OT  - neuromuscular transmission
EDAT- 2020/03/21 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/03/21 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/03/04 00:00 [revised]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/03/21 06:00 [entrez]
AID - S0306-4522(20)30152-4 [pii]
AID - 10.1016/j.neuroscience.2020.03.009 [doi]
PST - ppublish
SO  - Neuroscience. 2020 Jul 15;439:48-61. doi: 10.1016/j.neuroscience.2020.03.009. 
      Epub 2020 Mar 17.